Current knowledge of microRNA-mediated regulation of drug metabolism in humans

References

• Lu AY. Drug-metabolism research challenges in the new millennium: individual variability in drug therapy and drug safety. Drug Metab Dispos. 1998;26(12):1217–1222.
   PubMed Web of Science ®Google Scholar
• Zanger UM, Cytochrome SM. P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther. 2013;138(1):103–141.
   PubMed Web of Science ®Google Scholar
• Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281–297.
   PubMed Web of Science ®Google Scholar
• Lee RC, Feinbaum RL, Ambros V. The Celegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993;75(5):843–854.
   PubMed Web of Science ®Google Scholar
• Wightman B, Ha I, Ruvkun G. Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in Celegans. Cell. 1993;75(5):855–862.
   PubMed Web of Science ®Google Scholar
• Pasquinelli AE, Reinhart BJ, Slack F, et al. Conservation of the sequence and temporal expression of let-7 heterochronic regulatory RNA. Nature. 2000;408(6808):86–89.
   PubMed Web of Science ®Google Scholar
• Hammond SM. An overview of microRNAs. Adv Drug Deliv Rev. 2015;87:3–14.
   PubMed Web of Science ®Google Scholar
• Hinske LC, Galante PA, Kuo WP, et al. A potential role for intragenic miRNAs on their hosts’ interactome. BMC Genomics. 2010;11:533.
   PubMed Web of Science ®Google Scholar
• Curtis HJ, Sibley CR, Wood MJ. Mirtrons, an emerging class of atypical miRNA. Wiley Interdiscip Rev RNA. 2012;3(5):617–632.
   PubMed Web of Science ®Google Scholar
• Krol J, Loedige I, Filipowicz W. The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet. 2010;11(9):597–610.
   PubMed Web of Science ®Google Scholar
• Duursma AM, Kedde M, Schrier M, et al. miR-148 targets human DNMT3b protein coding region. Rna. 2008;14(5):872–877.
   PubMed Web of Science ®Google Scholar
• Takagi S, Nakajima M, Kida K, et al. MicroRNAs regulate human hepatocyte nuclear factor 4α, modulating the expression of metabolic enzymes and cell cycle. J Biol Chem. 2010;285(7):4415–4422.
   PubMed Web of Science ®Google Scholar
• Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 2005;120(1):15–20.
   PubMed Web of Science ®Google Scholar
• Alexiou P, Maragkakis M, Papadopoulos GL, et al. Lost in translation: an assessment and perspective for computational microRNA target identification. Bioinformatics. 2009;25(23):3049–3055.
   PubMed Web of Science ®Google Scholar
• Tsuchiya Y, Nakajima M, Takagi S, et al. MicroRNA regulates the expression of human cytochrome P450 1B1. Cancer Res. 2006;66(18):9090–9098.
   PubMed Web of Science ®Google Scholar
• Ramadoss P, Marcus C, Perdew GH. Role of the aryl hydrocarbon receptor in drug metabolism. Expert Opin Drug Metab Toxicol. 2005;1(1):9–21.
   PubMedGoogle Scholar
• Kondraganti SR, Fernandez-Salguero P, Gonzalez FJ, et al. Polycyclic aromatic hydrocarbon-inducible DNA adducts: evidence by 32P-postlabeling and use of knockout mice for Ah receptor-independent mechanisms of metabolic activation in vivo. Int J Cancer. 2003;103(1):5–11.
   PubMed Web of Science ®Google Scholar
• Moorthy B, Chu C, Carlin DJ. Polycyclic aromatic hydrocarbons: from metabolism to lung cancer. Toxicol Sci. 2015;145(1):5–15.
   PubMed Web of Science ®Google Scholar
• Choi YM, An S, Lee EM, et al. CYP1A1 is a target of miR-892a-mediated post-transcriptional repression. Int J Oncol. 2012;41(1):331–336.
   PubMed Web of Science ®Google Scholar
• Zhou SF, Yang LP, Zhou ZW, et al. Insights into the substrate specificity, inhibitors, regulation, and polymorphisms and the clinical impact of human cytochrome P450 1A2. Aaps J. 2009;11(3):481–494.
   PubMed Web of Science ®Google Scholar
• Chen Y, Zeng L, Wang Y, et al. The expression, induction and pharmacological activity of CYP1A2 are post-transcriptionally regulated by microRNA hsa-miR-132-5p. Biochem Pharmacol. 2017;145:178–191.
   PubMed Web of Science ®Google Scholar
• Shet MS, McPhaul M, Fisher CW, et al. Metabolism of the antiandrogenic drug (Flutamide) by human CYP1A2. Drug Metab Dispos. 1997;25(11):1298–1303.
   PubMed Web of Science ®Google Scholar
• Takamizawa J, Konishi H, Yanagisawa K, et al. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res. 2004;64(11):3753–3756.
   PubMed Web of Science ®Google Scholar
• Calin GA, Dumitru CD, Shimizu M, et al. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA. 2002;99(24):15524–15529.
   PubMed Web of Science ®Google Scholar
• Hayes CL, Spink DC, Spink BC, et al. 17β-Estradiol hydroxylation catalyzed by human cytochrome P450 1B1. Proc Natl Acad Sci USA. 1996;93(18):9776–9781.
   PubMed Web of Science ®Google Scholar
• Murray GI, Taylor MC, McFadyen MC, et al. Tumor-specific expression of cytochrome P450 CYP1B1. Cancer Res. 1997;57(14):3026–3031.
   PubMed Web of Science ®Google Scholar
• Ragavan N, Hewitt R, Cooper LJ, et al. CYP1B1 expression in prostate is higher in the peripheral than in the transition zone. Cancer Lett. 2004;215(1):69–78.
   PubMed Web of Science ®Google Scholar
• Chang I, Mitsui Y, Fukuhara S, et al. Loss of miR-200c up-regulates CYP1B1 and confers docetaxel resistance in renal cell carcinoma. Oncotarget. 2015;6(10):7774–7787.
   PubMedGoogle Scholar
• McFadyen MC, McLeod HL, Jackson FC, et al. Cytochrome P450 CYP1B1 protein expression: a novel mechanism of anticancer drug resistance. Biochem Pharmacol. 2001;62(2):207–212.
   PubMed Web of Science ®Google Scholar
• Mao M, Wu Z, Chen J. MicroRNA-187-5p suppresses cancer cell progression in non-small cell lung cancer (NSCLC) through down-regulation of CYP1B1. Biochem Biophys Res Commun. 2016;478(2):649–655.
   PubMed Web of Science ®Google Scholar
• Sato S, Shirakawa H, Tomita S, et al. Low-dose dioxins alter gene expression related to cholesterol biosynthesis, lipogenesis, and glucose metabolism through the aryl hydrocarbon receptor-mediated pathway in mouse liver. Toxicol Appl Pharmacol. 2008;229(1):10–19.
   PubMed Web of Science ®Google Scholar
• Kurtz CL, Fannin EE, Toth CL, et al. Inhibition of miR-29 has a significant lipid-lowering benefit through suppression of lipogenic programs in liver. Sci Rep. 2015;5:12911.
   PubMed Web of Science ®Google Scholar
• Huang TC, Chang HY, Chen CY, et al. Silencing of miR-124 induces neuroblastoma SK-N-SH cell differentiation, cell cycle arrest and apoptosis through promoting AHR. FEBS Lett. 2011;585(22):3582–3586.
   PubMed Web of Science ®Google Scholar
• Nakano M, Fukami T, Gotoh S, et al. RNA editing modulates human hepatic aryl hydrocarbon receptor expression by creating microRNA recognition sequence. J Biol Chem. 2016;291(2):894–903.
   PubMed Web of Science ®Google Scholar
• Nishikura K. A-to-I editing of coding and non-coding RNAs by ADARs. Nat Rev Mol Cell Biol. 2016;17(2):83–96.
   PubMed Web of Science ®Google Scholar
• Slotkin W, Adenosine-To-Inosine NK. RNA editing and human disease. Genome Med. 2013;5(11):105.
   PubMedGoogle Scholar
• Oda Y, Nakajima M, Mohri T, et al. Aryl hydrocarbon receptor nuclear translocator in human liver is regulated by miR-24. Toxicol Appl Pharmacol. 2012;260(3):222–231.
   PubMed Web of Science ®Google Scholar
• Yamano S, Tatsuno J, Gonzalez FJ. The CYP2A3 gene product catalyzes coumarin 7-hydroxylation in human liver microsomes. Biochemistry. 1990;29(5):1322–1329.
   PubMed Web of Science ®Google Scholar
• Ding S, Bg L, Friedberg T, et al. Expression and alternative splicing of the cytochrome P-450 CYP2A7. Biochem J. 1995;306:161–166.
   PubMed Web of Science ®Google Scholar
• Nakajima M, Yamamoto T, Nunoya K, et al. Role of human cytochrome P4502A6 in C-oxidation of nicotine. Drug Metab Dispos. 1996;24(11):1212–1217.
   PubMed Web of Science ®Google Scholar
• Tiano HF, Hosokawa M, Chulada PC, et al. Retroviral mediated expression of human cytochrome P450 2A6 in C3H/10T1/2 cells confers transformability by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK). Carcinogenesis. 1993;14(7):1421–1427.
   PubMed Web of Science ®Google Scholar
• Nakajima M, Kuroiwa Y, Yokoi T. Interindividual differences in nicotine metabolism and genetic polymorphisms of human CYP2A6. Drug Metab Rev. 2002;34(4):865–877.
   PubMed Web of Science ®Google Scholar
• Nakano M, Fukushima Y, Yokota S, et al. CYP2A7 pseudogene transcript affects CYP2A6 expression in human liver by acting as a decoy for miR-126*. Drug Metab Dispos. 2015;43(5):703–712.
   PubMed Web of Science ®Google Scholar
• Lamba V, Lamba J, Yasuda K, et al. Hepatic CYP2B6 expression: gender and ethnic differences and relationship to CYP2B6 genotype and CAR (constitutive androstane receptor) expression. J Pharmacol Exp Ther. 2003;307(3):906–922.
   PubMed Web of Science ®Google Scholar
• Sueyoshi T, Kawamoto T, Zelko I, et al. The repressed nuclear receptor CAR responds to phenobarbital in activating the human CYP2B6 gene. J Biol Chem. 1999;274(10):6043–6046.
   PubMed Web of Science ®Google Scholar
• Jin Y, Yu D, Tolleson WH, et al. MicroRNA hsa-miR-25-3p suppresses the expression and drug induction of CYP2B6 in human hepatocytes. Biochem Pharmacol. 2016;113:88–96.
   PubMed Web of Science ®Google Scholar
• Burgess KS, Ipe J, Swart M, et al. Variants in the CYP2B6 3ʹUTR alter in vitro and in vivo CYP2B6 activity: potential role of microRNAs. Clin Pharmacol Ther. forthcoming.
   Google Scholar
• Goldstein JA. Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br J Clin Pharmacol. 2001;52(4):349–355.
   PubMed Web of Science ®Google Scholar
• Zhang SY, Surapureddi S, Coulter S, et al. Human CYP2C8 is post-transcriptionally regulated by microRNAs 103 and 107 in human liver. Mol Pharmacol. 2012;82(3):529–540.
   PubMed Web of Science ®Google Scholar
• Yu D, Green B, Marrone A, et al. Suppression of CYP2C9 by microRNA hsa-miR-128-3p in human liver cells and association with hepatocellular carcinoma. Sci Rep. 2015;5:8534.
   PubMed Web of Science ®Google Scholar
• Yu D, Green B, Tolleson WH. MicroRNA hsa-miR-29a-3p modulates CYP2C19 in human liver cells. Biochem Pharmacol. 2015;98(1):215–223.
   PubMed Web of Science ®Google Scholar
• Rieger JK, Reutter S, Hofmann U, et al. Inflammation-associated microRNA-130b down-regulates cytochrome P450 activities and directly targets CYP2C9. Drug Metab Dispos. 2015;43(6):884–888.
   PubMed Web of Science ®Google Scholar
• Rendic S. Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002;34(1–2):83–448.
   PubMed Web of Science ®Google Scholar
• Shimada T, Yamazaki H, Mimura M, et al. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther. 1994;270(1):414–423.
   PubMed Web of Science ®Google Scholar
• Hart SN, Wang S, Nakamoto K, et al. Genetic polymorphisms in cytochrome P450 oxidoreductase influence microsomal P450-catalyzed drug metabolism. Pharmacogenet Genomics. 2008;18(1):11–24.
   PubMed Web of Science ®Google Scholar
• Bock KW, Schrenk D, Forster A, et al. The influence of environmental and genetic factors on CYP2D6, CYP1A2 and UDP-glucuronosyltransferases in man using sparteine, caffeine, and paracetamol as probes. Pharmacogenetics. 1994;4(4):209–218.
   PubMedGoogle Scholar
• Zeng L, Chen Y, Wang Y, et al. MicroRNA hsa-miR-370-3p suppresses the expression and induction of CYP2D6 by facilitating mRNA degradation. Biochem Pharmacol. 2017;140:139–149.
   PubMed Web of Science ®Google Scholar
• Bolt HM, Roos PH, Thier R. The cytochrome P-450 isoenzyme CYP2E1 in the biological processing of industrial chemicals: consequences for occupational and environmental medicine. Int Arch Occup Environ Health. 2003;76(3):174–185.
   PubMed Web of Science ®Google Scholar
• Bièche I, Narjoz C, Asselah T, et al. Reverse transcriptase-PCR quantification of mRNA levels from cytochrome (CYP)1, CYP2 and CYP3 families in 22 different human tissues. Pharmacogenet Genomics. 2007;17(9):731–742.
   PubMed Web of Science ®Google Scholar
• Sumida A, Kinoshita K, Fukuda T, et al. Relationship between mRNA levels quantified by reverse transcription-competitive PCR and metabolic activity of CYP3A4 and CYP2E1 in human liver. Biochem Biophys Res Commun. 1999;262(2):499–503.
   PubMed Web of Science ®Google Scholar
• Mohri T, Nakajima M, Fukami T, et al. Human CYP2E1 is regulated by miR-378. Biochem Pharmacol. 2010;79(7):1045–1052.
   PubMed Web of Science ®Google Scholar
• Nakano M, Mohri T, Fukami T, et al. Single-nucleotide polymorphisms in cytochrome P450 2E1 (CYP2E1) 3ʹ-untranslated region affect the regulation of CYP2E1 by miR-570. Drug Metab Dispos. 2015;43(10):1450–1457.
   PubMed Web of Science ®Google Scholar
• Ramamoorthy A, Skaar TC. In silico identification of microRNAs predicted to regulate the drug metabolizing cytochrome P450 genes. Drug Metab Lett. 2011;5(2):126–131.
   PubMedGoogle Scholar
• Jeffries CD, Fried HM, Perkins DO, et al. Nuclear and cytoplasmic localization of neural stem cell microRNAs. Rna. 2011;17(4):675–686.
   PubMed Web of Science ®Google Scholar
• Kim DH, Saetrom P, Snøve O Jr, et al. MicroRNA-directed transcriptional gene silencing in mammalian cells. Proc Natl Acad Sci USA. 2008;105(42):16230–16235.
   PubMed Web of Science ®Google Scholar
• Miao L, Yao H, Li C1, et al. A dual inhibition: microRNA-552 suppresses both transcription and translation of cytochrome P450 2E1. Biochim Biophys Acta. 2016;1859(4):650–662.
   PubMed Web of Science ®Google Scholar
• Wang Y, Yu D, Tolleson WH, et al. A systematic evaluation of microRNAs in regulating human hepatic CYP2E1. Biochem Pharmacol. 2017;138:174–184.
   PubMed Web of Science ®Google Scholar
• Bertz RJ, Granneman GR. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet. 1997;32(3):210–258.
   PubMed Web of Science ®Google Scholar
• Martínez-Jiménez CP, Jover R, Donato MT, et al. Transcriptional regulation and expression of CYP3A4 in hepatocytes. Curr Drug Metab. 2007;8(2):185–194.
   PubMed Web of Science ®Google Scholar
• Pan YZ, Gao W, Yu AM. MicroRNAs regulate CYP3A4 expression via direct and indirect targeting. Drug Metab Dispos. 2009;37(10):2112–2117.
   PubMed Web of Science ®Google Scholar
• Shi Y, Liu Y, Wei Z, et al. Hsa-miR-27a is involved in the regulation of CYP3A4 expression in human livers from Chinese Han population. Pharmacogenomics. 2015;16(12):1379–1386.
   PubMed Web of Science ®Google Scholar
• Wei Z, Jiang S, Zhang Y, et al. The effect of microRNAs in the regulation of human CYP3A4: a systematic study using a mathematical model. Sci Rep. 2014;4:4283.
   PubMed Web of Science ®Google Scholar
• Yan L, Liu J, Zhao Y, et al. Suppression of miR-628-3p and miR-641 is involved in rifampin-mediated CYP3A4 induction in HepaRG cells. Pharmacogenomics. 2017;18(1):57–64.
   PubMed Web of Science ®Google Scholar
• Liu JE, Ren B, Tang L, et al. The independent contribution of miRNAs to the missing heritability in CYP3A4/5 functionality and the metabolism of atorvastatin. Sci Rep. 2016;6:26544.
   PubMed Web of Science ®Google Scholar
• Takagi S, Nakajima M, Mohri T, et al. Post-transcriptional regulation of human pregnane X receptor by micro-RNA affects the expression of cytochrome P450 3A4. J Biol Chem. 2008;283(15):9674–9680.
   PubMed Web of Science ®Google Scholar
• Vachirayonstien T, Yan B. MicroRNA-30c-1-3p is a silencer of the pregnane X receptor by targeting the 3ʹ-untranslated region and alters the expression of its target gene cytochrome P450 3A4. Biochim Biophys Acta. 2016;1859(9):1238–1244.
   PubMedGoogle Scholar
• Sharma D, Turkistani AA, Chang W, et al. Negative regulation of human pregnane X receptor by microRNA-18a-5p: evidence for suppression of microRNA-18a-5p expression by rifampin and rilpivirine. Mol Pharmacol. 2017;92(1):48–56.
   PubMed Web of Science ®Google Scholar
• Oda Y, Nakajima M, Tsuneyama K, et al. Retinoid X receptor α in human liver is regulated by miR-34a. Biochem Pharmacol. 2014;90(2):179–187.
   PubMed Web of Science ®Google Scholar
• Porter TD. The roles of cytochrome b5 in cytochrome P450 reactions. J Biochem Mol Toxicol. 2002;16(6):311–316.
   PubMed Web of Science ®Google Scholar
• Takahashi K, Oda Y, Toyoda Y, et al. Regulation of cytochrome b5 expression by miR-223 in human liver: effects on cytochrome P450 activities. Pharm Res. 2014;31(3):780–794.
   PubMed Web of Science ®Google Scholar
• Oda S, Fukami T, Yokoi T, et al. A comprehensive review of UDP-glucuronosyltransferase and esterases for drug development. Drug Metab Pharmacokinet. 2015;30(1):30–51.
   PubMed Web of Science ®Google Scholar
• Mackenzie PI, Bock KW, Burchell B, et al. Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily. Pharmacogenet Genomics. 2005;15(10):677–685.
   PubMed Web of Science ®Google Scholar
• Dluzen DF, Sun D, Salzberg AC, et al. Regulation of UDP-glucuronosyltransferase 1A1 expression and activity by microRNA 491-3p. J Pharmacol Exp Ther. 2014;348(3):465–477.
   PubMed Web of Science ®Google Scholar
• Papageorgiou I, Court MH. Identification and validation of microRNAs directly regulating the UDP-glucuronosyltransferase 1A subfamily enzymes by a functional genomics approach. Biochem Pharmacol. 2017;137:93–106.
   PubMed Web of Science ®Google Scholar
• Tatsumi T, Tokumitsu SNakano M, et al. Mir-141-3p commonly regulates human ugt1a isoforms via different mechanisms. Drug Metab Pharmacokinet. in press.
   Google Scholar
• Papageorgiou I, Freytsis M, Court MH. Transcriptome association analysis identifies miR-375 as a major determinant of variable acetaminophen glucuronidation by human liver. Biochem Pharmacol. 2016;117:78–87.
   PubMed Web of Science ®Google Scholar
• Izukawa T, Nakajima M, Fujiwara R, et al. Quantitative analysis of UDP-glucuronosyltransferase (UGT) 1A and UGT2B expression levels in human livers. Drug Metab Dispos. 2009;37(8):1759–1768.
   PubMed Web of Science ®Google Scholar
• Dluzen DF, Sutliff AK, Chen G, et al. Regulation of UGT2B expression and activity by miR-216b-5p in liver cancer cell lines. J Pharmacol Exp Ther. 2016;359(1):182–193.
   PubMed Web of Science ®Google Scholar
• Wijayakumara DD, Mackenzie PI, McKinnon RA, et al. Regulation of UDP-Glucuronosyltransferases UGT2B4 and UGT2B7 by MicroRNAs in liver cancer cells. J Pharmacol Exp Ther. 2017;361(3):386–397.
   PubMed Web of Science ®Google Scholar
• Papageorgiou I, Court MH. Identification and validation of the microRNA response elements in the 3ʹ-untranslated region of the UDP glucuronosyltransferase (UGT) 2B7 and 2B15 genes by a functional genomics approach. Biochem Pharmacol. 2017;146:199–213.
   PubMed Web of Science ®Google Scholar
• Wijayakumara DD, Hu DG, Meech R, et al. Regulation of human UGT2B15 and UGT2B17 by miR-376c in prostate cancer cell lines. J Pharmacol Exp Ther. 2015;354(3):417–425.
   PubMed Web of Science ®Google Scholar
• Margaillan G, Lévesque É, Guillemette C. Epigenetic regulation of steroid inactivating UDP-glucuronosyltransferases by microRNAs in prostate cancer. Biochem Mol Biol. 2016;155(Part A):85–93.
   Google Scholar
• Gamage N, Barnett A, Hempel N, et al. Human sulfotransferases and their role in chemical metabolism. Toxicol Sci. 2006;90(1):5–22.
   PubMed Web of Science ®Google Scholar
• Hildebrandt M, Adjei A, Weinshilboum R, et al. Very important pharmacogene summary: sulfotransferase 1A1. Pharmacogenet Genomics. 2009;19(6):404–406.
   PubMed Web of Science ®Google Scholar
• Jones AL, Roberts RC, Coughtrie MW. The human phenolsulphotransferase polymorphism is determined by the level of expression of the enzyme protein. Biochem J. 1993;296(Pt 2):287–290.
   PubMedGoogle Scholar
• Yu X, Dhakal IB, Beggs M, et al. Functional genetic variants in the 3ʹ-untranslated region of sulfotransferase isoform 1A1 (SULT1A1) and their effect on enzymatic activity. Toxicol Sci. 2010;118(2):391–403.
   PubMed Web of Science ®Google Scholar
• Rieger JK, Klein K, Winter S, et al. Expression variability of absorption, distribution, metabolism, excretion-related microRNAs in human liver: influence of nongenetic factors and association with gene expression. Drug Metab Dispos. 2013;41(10):1752–1762.
   PubMed Web of Science ®Google Scholar
• Lamba V, Ghodke Y, Guan W, et al. microRNA-34a is associated with expression of key hepatic transcription factors and cytochromes P450. Biochem Biophys Res Commun. 2014;445(2):404–411.
   PubMed Web of Science ®Google Scholar
• Iwai N, Naraba H. Polymorphisms in human pre-miRNAs. Biochem Biophys Res Commun. 2005;331(4):1439–1444.
   PubMed Web of Science ®Google Scholar
• Duan R, Pak C, Jin P. Single nucleotide polymorphism associated with mature miR-125a alters the processing of pri-miRNA. Hum Mol Genet. 2007;16(9):1124–1131.
   PubMed Web of Science ®Google Scholar
• Takahashi K, Tatsumi N, Fukami T, et al. Integrated analysis of rifampicin-induced microRNA and gene expression changes in human hepatocytes. Drug Metab Pharmacokinet. 2014;29(4):333–340.
   PubMed Web of Science ®Google Scholar
• Ramamoorthy A, Liu Y, Philips S, et al. Regulation of microRNA expression by rifampin in human hepatocytes. Drug Metab Dispos. 2013;41(10):1763–1768.
   PubMed Web of Science ®Google Scholar
• Koufaris C, Wright J, Osborne M, et al. Time and dose-dependent effects of phenobarbital on the rat liver miRNAome. Toxicology. 2013;314(23):247–253.
   PubMedGoogle Scholar
• Singh NP, Singh UP, Guan H, et al. Prenatal exposure to TCDD triggers significant modulation of microRNA expression profile in the thymus that affects consequent gene expression. PLoS One. 2012;7(9):e45054.
   PubMed Web of Science ®Google Scholar
• Jilek JL, Tian Y, Yu AM. Effects of microRNA-34a on the pharmacokinetics of cytochrome P450 probe drugs in mice. Drug Metab Dispos. 2017;45(5):512–522.
   PubMed Web of Science ®Google Scholar
• Titze-de-Almeida R, David C, Titze-de-Almeida SS. The race of 10 synthetic RNAi-based drugs to the pharmaceutical market. Pharm Res. 2017;34(7):1339–1363.
   PubMed Web of Science ®Google Scholar
• Li Z, Rana TM. Therapeutic targeting of microRNAs: current status and future challenges. Nat Rev Drug Discov. 2014;13(8):622–638.
   PubMed Web of Science ®Google Scholar
• Chowdhary V, Teng KY, Thakral S, et al. miRNA-122 protects mice and human hepatocytes from acetaminophen toxicity by regulating cytochrome P450 family 1 subfamily A member 2 and family 2 subfamily E member 1 expression. Am J Pathol. 2017;187(12):2758–2774.
   PubMed Web of Science ®Google Scholar